A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells
PHASE1CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
Not specified
Study Completion Date
July 31, 1993
Conditions
HIV Infections
Interventions
BIOLOGICAL
gp160 Vaccine (MicroGeneSys)
Trial Locations (1)
10016
NY Univ. HIV/AIDS CRS, New York
All Listed Sponsors
collaborator
Protein Sciences Corporation
INDUSTRY
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000667 - A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells | Biotech Hunter | Biotech Hunter